To analyze the cost of glaucoma medical therapy and compare it with that of surgical management in Nigeria. Methods: The cost of glaucoma drugs and that of surgical therapy in patients who attended the eye clinic of the University of Benin Teaching Hospital, Benin City, Nigeria, between December 2002 and November 2008 were calculated over a 3 year period of follow-up. Costs of medical and surgical therapy were compared based on November 2008 estimates. Results: One hundred and eight patients met the inclusion criteria of the study, of which, 90 patients (83.33%) received medical therapy and 18 patients (16.67%) underwent surgery. The most expensive drugs were the prostaglandin analogues, travoprost (Travatan) and latanoprost (Xalatan). The least expensive topical drugs were beta-blockers and miotics. The mean annual cost of medical treatment was US$ 273.47±174.42 (range, $41.54 to $729.23) while the mean annual cost of surgical treatment was US$ 283.78±202.95 (range, $61.33 to $592.63). There was no significant difference between the mean costs of medical and surgical therapy over the 3-year period (P = 0.37). Older age (P = 0.02) and advanced glaucoma (P < 0.001) were associated with higher costs of therapy.
INTRODuCTION
Glaucoma is the second leading cause of blindness worldwide and is estimated to have affected 60.5 million people in 2010, increasing to 79.6 million by 2020. 1 In glaucoma, the optic nerve is progressively damaged, causing defects in the visual field, usually asymptomatic until central vision is affected. 2, 3 Unfortunately, by the time characteristic visual field defects are demonstrable, one third or more of the optic nerve fibers are already damaged; by the time patients complain of significant field loss, the remaining axons are probably 10% or fewer. 4 The purpose of glaucoma treatment is to preserve visual function while minimizing adverse effects of therapy, thereby enhancing patient health and quality of life. 2, 5, 6 Although trabeculectomy is regarded as the standard form of treatment for patients with primary open angle glaucoma in developing countries including Nigeria, 7 are treated medically. This is especially true in teaching hospitals and other tertiary centers which are concentrated in urban areas, partly because of patients' unwillingness to undergo surgery (since there will be no improvement in vision) and partly due to fear of surgery. 8 Primary open angle glaucoma (POAG) requires lifelong monitoring; this places an increasing financial strain on the health service system as the elderly population increases. The volume and cost of glaucoma drugs have been shown to have increased dramatically in both Northern Ireland and the Republic of Ireland from 1996 to 2003, probably as a result of a combination of changing demographics a n d a c h a n g i n g a p p r o a c h t o w a r d s t h e management of patients with glaucoma and ocular hypertension. 9 It has been demonstrated in Europe, that resource utilization and direct medical costs of glaucoma management increase with worsening disease severity. 10 This has also been shown in the United States. 11 However, there is a paucity of information on glaucoma therapy costs in Sub-Saharan Africa where patients frequently present with advanced stages of the disease. 12 The purpose of this study is to analyze the cost of glaucoma drugs and compare it with that of surgical therapy in Benin City, Nigeria.
METHODS
Data was obtained from the medical records of all patients diagnosed with POAG and normal tension glaucoma, who attended the eye clinic of the University of Benin Teaching Hospital, Benin City, Nigeria, between December 2002 and November 2008. The patients were included in the study if they had at least 3 years of continuous follow up. Only patients who were compliant with therapy were included in the study. Patients were included in the surgery group if they had primary trabeculectomy or had a short period of medical therapy, not exceeding one month, before trabeculectomy. Patients were excluded if they had less than 3 years of continuous follow up, concomitant ocular diseases likely to affect glaucoma treatment-related resource consumption, or were subsequently enrolled at any time in a clinical trial. Patients who were not compliant with therapy were also excluded.
C o l l e c t e d d a t a i n c l u d e d p a t i e n t demographics, number of ophthalmology clinic visits, number and type of glaucoma medications and surgeries, perioperative drugs in subjects who had undergone glaucoma surgery, and any postoperative procedure. All clinical tests documented in the files were also recorded. Glaucomatous optic disc appearance was categorized using the modified grading by Jay 13 as follows: a. Stage 1: Suspicious shape of the optic nerve, but cup/disc ratio less than or equal to 0.6. b. Stage 2: Pathological: cup/disc ratio greater than 0.6, but less than 0.9. c. Stage 3: End stage: cup/disc ratio greater than or equal to 0.9. The hospital pharmacy, the accounting department, and four nearby pharmacies were consulted to provide available unit costs for surgical procedures and medications extracted from the case records. The direct annual cost of treatment per person-year, including a breakdown of costs attributed to glaucoma surgeries, cataract extractions, and glaucoma medications, was calculated for all patients. The costs were measured in Nigerian Naira (N) and expressed in United States Dollars ($). The exchange rate during the period of the study was N 130.00 to $1.00. The costs of drugs or surgery used for the study were based on estimates in November 2008.
A 5 ml bottle of an ocular medication prescribed twice daily or its equivalent (for example, a 2.5 ml bottle of a medication prescribed once daily) was assumed to represent a one-month supply for any given patient. Data on medication usage were collected at every visit and patients were assumed to adhere fully to medical regimens unless otherwise noted in the case records. The cost of therapy was calculated from the perspective of patients and only direct costs of drugs and surgery were considered. Only out-of-pocket payments were considered as none of the subjects had insurance policies. Socio-economic status was classified using the patient's occupation as modified from the British Registrar General's Classification. 14 Class I comprises higher professions, such as medical doctors, engineers, businessmen, etc. Class II includes lesser professions such as nurses, teachers, etc. Class III consists of skilled workers such as typists, clerks, technicians, etc. Class IV comprises semi-skilled workers such as petty traders, machine operators, etc. Class V includes unskilled workers such as subsistence farmers, housewives, etc.
Data Analysis
In order to calculate the number of resources consumed per person-time, the total number of each consumed resource was added and then divided by the total number of follow-up visits. For patients who underwent surgery, the cost of surgery, hospital stay, and preoperative, intraoperative and postoperative drugs were calculated as the total cost of surgery. If the patient needed additional drugs to control intraocular pressure (IOP) or additional surgery for complications, these were also added to the cost of trabeculectomy in the surgery group. Data obtained from this study were analyzed using the Instat GraphPad version 2.05a software (GraphPad Software Inc., La Jolla, CA, USA). Mean and standard deviations (SD) of the costs of drugs and surgery were compared using the student t-test. 95% confidence intervals (95%CI) and the standard error of mean (SEM) were also determined. P-values less than 0.05 were considered significant. Factors affecting the cost of glaucoma therapy were determined using the student t-test and the one way analysis of variance (ANOVA) where appropriate.
RESuLTS
Overall, 308 new patients who attended the eye clinic during the period of the study were diagnosed with POAG or normal tension glaucoma. Of these, 108 subjects (35.06%) met the inclusion criteria which included 78 male (72.22%) and 30 female (27.78%) patients with mean age of 58.14±10.8 (range 22 to 76) years.
The age and sex distribution of study subjects is shown in figure 1 The lowest annual cost of medical therapy w a s a s s o c i a t e d w i t h m o n o t h e r a p y w i t h timolol maleate 0.5% drops, while the highest annual cost of medical therapy was related to combination therapy with latanoprost 0.005% (Xalatan) or travoprost (Travatan), dorzolamide (Trusopt) or brinzolamide (Azopt), and timolol maleate 0.5% (Timoptol).
The cost of trabeculectomy in the University of Benin Teaching Hospital was $ 103.85. The cost of perioperative drugs was $ 46.31, and that for an average 4-day hospital stay was $ 33.85. Thus, the total cost of trabeculectomy per eye was $ 184.00.
The mean annual cost of surgical treatment was US$ 283. Patients with the lowest annual cost of surgical therapy were those who had successful trabeculectomy without additional need for medical therapy for IOP control. Only 3 of 18 patients (16.67%) had complete success with trabeculectomy and did not require additional medical treatment. Patients with the highest annual cost of surgical therapy were those who had unsuccessful trabeculectomy with additional need for medical therapy for IOP control and cataract surgery.
There was no significant difference between the mean cost of medical and surgical therapy (t=1.134, df=2, P=0.37).
The Table 2 . Commonly available antiglaucoma drugs and their unit cost surgery. Older age and advanced stages of glaucoma were significantly associated with higher costs of therapy (Table 5) .
DISCuSSION
Large-scale, prospective, randomized multicenter trials have provided evidence that lowering IOP in glaucoma can arrest the progression to blindness. 15, 16 Glaucoma is most commonly treated with topical medications in developed countries; surgery is usually performed if medications fails to lower IOP adequately. 6 Glaucoma drugs are commonly divided into six main groups: prostaglandin analogues, β-blockers, miotics, sympathomimetics, carbonic anhydrase inhibitors, and combination drugs. For more than 20 years, topical β-blockers dominated the market, overtaking the older miotics and sympathomimetics in volume of sales. 9 However, in the past decade a number of new drugs have been introduced, which have had a profound effect on the management of glaucoma. 6, 9 The majority of patients in the present study were managed medically which is contrary to what is expected based on reports that trabeculectomy is the standard form of treatment for patients with primary open angle glaucoma in developing countries. 7 This may reflect a change in the choice of therapy, probably because of the range of effective drugs now available, and the poor acceptability of glaucoma surgery in Benin City, Nigeria. 8 A low proportion of surgical management has also been reported from Western Nigeria, where only 8.2% of a series of glaucoma patients had trabeculectomy. 17 Although the majority of our patients had tertiary education and belonged to social classes I and II, the annual income in Nigeria is much less than that of developed countries. Subjects with tertiary education 18 This amount is just slightly higher than the price of latanoprost or travoprost. These figures imply that a patient on minimum wage cannot afford a combination therapy which includes prostaglandin analogues, even if he/she spends all his/her income. The average patient will also have to save all of his/her monthly income for 5 months to afford trabeculectomy in one eye. Even patients in higher professions still have to spend a significant amount of their earnings to be able to pay for combination therapy or surgery.
T h e m o s t e x p e n s i v e d r u g s w e r e t h e prostaglandin analogues, travoprost (Travatan) and latanoprost (Xalatan). Other expensive drugs included topical carbonic anhydrase inhibitors, dorzolamide and brinzolamide. Although other drugs, such as brimonidine (Alphagan), are available in Benin City, none of the patients in this series used them. These drugs were usually not prescribed because they were not commonly available. The least expensive topical drugs were β-blockers and miotics. The oral carbonic anhydrase inhibitor, acetazolamide, was also inexpensive. Although acetazolamide is not indicated for long term use, it was commonly prescribed because of its efficacy in the short term and because poor patients could afford a few tablets at a time, thus reducing non-compliance due to the cost of drugs.
There was no significant difference in the mean annual, monthly, or daily costs of medical versus surgical treatment. The average cost of surgical therapy was however, slightly higher over a 3-year period. This is in contrast to what is expected, since surgical patients are expected to pay once for their procedure while patients on medical therapy continue to purchase drugs indefinitely. Eventually, medical therapy should become more expensive. Unfortunately, many glaucoma patients who had undergone trabeculectomy needed additional medical therapy for IOP control and may also have incurred extra costs for management of postoperative complications such as cataracts, infection, bleb-related complications, etc. Trabeculectomy tends to fail over time because of fibroblastic proliferation and subconjunctival fibrosis which occurs during the process of wound healing. 19 Adjunctive use of antifibrotic agents such as mitomycin C at the site of surgery has significantly reduced the risk of bleb failure. 20 Sherwood et al 21 have argued that it is wrong to believe that a one-step surgery will save money. Their 1991 estimates show that the cost of bilateral uncomplicated glaucoma surgery roughly equals 8 years of medical treatment. Since about one third of the patients may need additional medical therapy or reoperations for failed surgery, premature cataract extraction, and other complications, the final cost of surgery may be even more. In the current study, patients who had complications and required additional procedures had the highest cost of surgical therapy.
The lowest cost of medical therapy was observed for monotherapy with timolol maleate 0.5% which was slightly lower than that of successful and uncomplicated trabeculectomy not requiring additional medical therapy. However if these two groups of patients had been followed up for up to 5 years, the mean monthly cost of surgery ($3.06) would have been lower than the mean monthly cost of medical therapy ($3.46). If they were followed up for even longer, the difference would become more significant. Unfortunately, most of our glaucoma patients are usually lost to follow-up after a few years and many African patients will eventually have poorly controlled IOP after surgery because of the propensity for fibrosis. These patients will need additional medical therapy, revision of trabeculectomy, or repeat surgery, thus increasing the cost of surgical therapy.
Older age and late stages of glaucoma were significantly associated with higher costs of glaucoma therapy. This is because patients who present with advanced disease are treated more vigorously with more medications and surgery. In these patients the target IOP is set lower because optic nerve damage is
